Answers are grounded in this paper and cite their sources.
subtypes and coexisting mutations may affect TKI efficacy. This review highlights the mutation spectrum of Asian NSCLC patients, particularly focusing on concurrent mutations and their impact on EGFR-TKI response. We also discuss evolving treatment strategies and summarize ongoing clinical trials targeting comutation scenarios. These insights may help guide personalized therapy decisions and provide directions for future research.
No takes yet. Share an insight, caveat, or question.
Jing et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: